...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion.
【24h】

Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion.

机译:用纤溶酶进行导管定向的血栓内溶栓治疗,用于治疗急性下肢动脉阻塞。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Catheter-directed thrombolysis is an important treatment option for many patients with acute lower extremity ischemia due to arterial and/or graft thrombosis. A growing body of evidence demonstrates that thrombolytic therapy for acute limb ischemia reduces the need for amputation; however, bleeding complications are more likely with lytic therapy. New direct-acting fibrinolytic compounds are being developed that facilitate thrombolysis while reducing the risk of bleeding. Plasmin, the active enzyme produced by all plasminogen activators, works directly upon thrombus and is neutralized instantly in the systemic circulation. This report reviews the principles for effective catheter directed thrombolysis for acute arterial occlusions and describes the development and evaluation of the new thrombolytic, plasmin.
机译:对于许多由于动脉和/或移植物血栓形成而导致的急性下肢缺血的患者,导管溶栓治疗是一种重要的治疗选择。越来越多的证据表明,针对急性肢体缺血的溶栓治疗可减少截肢的需要。但是,溶血疗法更容易引起出血并发症。正在开发新的直接作用的纤溶化合物,该化合物可促进溶栓同时降低出血风险。纤溶酶是所有纤溶酶原激活剂产生的活性酶,直接作用于血栓,并在全身循环中立即被中和。该报告回顾了针对急性动脉阻塞的有效导管定向溶栓治疗的原理,并描述了新型溶栓蛋白纤溶酶的开发和评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号